Compare LND & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LND | CABA |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.6M | 339.1M |
| IPO Year | 2010 | 2019 |
| Metric | LND | CABA |
|---|---|---|
| Price | $3.21 | $1.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 66.0K | ★ 4.8M |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $48.42 | N/A |
| Revenue Next Year | $6.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.12 | $1.32 |
| 52 Week High | $4.45 | $4.23 |
| Indicator | LND | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 33.69 |
| Support Level | N/A | N/A |
| Resistance Level | $3.81 | $2.14 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 14.77 | 25.00 |
Brasilagro - Cia Bras de Prop Agricolas is a Brazil-based company, engaged in the acquisition, development, operation, and sale of rural properties suitable for agricultural activities. The business activity of the firm is operated through Real estate, Grains, Sugarcane, Cattle rising, Cotton, and Other segments. The Grains segment is involved in the production and sale of soybean and corn. The Sugarcane segment includes the sale of raw product. The Real Estate segment presents the P&L from operations carried out in the company's subsidiaries. The Cattle Raising segment consists of producing and selling beef calves after weaning, which characterizes the activity as breeding and the Other segment engages in other corporate activities. The majority of revenue is earned from Grain Segment.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.